Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2025 | ARC-20: casdatifan monotherapy in pre-treated clear cell renal cell carcinoma

Bradley McGregor • 13 Feb 2025

GU Cancers 2025

ARC-20 PEAK-1

Bradley McGregor, MD, Dana-Farber Cancer Institute, Boston, MA, discusses results from the Phase I ARC-20 trial (NCT05536141) of casdatifan monotherapy in patients with clear cell renal cell carcinoma (ccRCC) previously treated with PD-(L)1 and VEGFR-TKI therapies. Casdatifan showed promising activity across all risk groups, with manageable safety signals, including anemia and hypoxia. Based on these findings, casdatifan will be investigated in combination with cabozantinib in the Phase III PEAK-1 trial. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.